摘要
目的:探讨胃癌患者化疗前后可溶性白细胞介素2受体(sIL-2R)和可溶性白细胞介素6受体(sIL-6R)水平的变化及意义。方法:将在我院治疗的45例胃癌患者作为观察组,我院体检中心经体检合格的45例正常人作为对照组。以酶联免疫吸附试验检测观察组患者化疗前后的sIL-2R和sIL-6R水平并与对照组做对照。结果:胃癌患者化疗前血清sIL-2R和sIL-6R水平明显高于对照组(P<0.01)。化疗6个月后,观察组未复发病例中sIL-2R,sIL-6R显著降低,与对照组比较无统计学意义(P>0.05),复发者又回升至化疗前水平(P<0.05)。结论:检测胃癌患者血清中sIL-2R和sIL-6R含量的变化可作为胃癌患者诊断和疗效观察的参考。
Objective ：To explove the clinical significance of changes of serum slL -2R and sIL -6R levels after chemotherapy in patients with cancer. Methods：The serum sIL- 2R and sIL -6R in 45 patients with malignant solid tumor were measured by enzyme -linked immunosorbent assay. Results：Be- fore chemotherapy, serum slL - 2R and sIL - 6R levels in the patients were significantly higher （ P 〈 0. 01 ）. Six months after chemotherapy, in 45 patients without recurrence the levels were dropped markedly. Compared with the control group had no statistical significance （ P 〉 0.05 ） ,recurrence and returned to the level before chemotherapy （ P 〈 0.05 ）. Conclusion： Determination of serum levels of sIL - 2R and sIL - 6R might be useful for diagnosis and predicting therapeutic effects after chemothempyin patients with gastric cancer.
出处
《护理实践与研究》
2013年第12期14-15,共2页
Nursing Practice and Research
